Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

Q1 Revenue Grew, Beat Consensus

 
• By Mandy Jackson
  
With its next big Phase III readouts in 2026 and beyond, Leqembi remains the biggest focus for Biogen investors (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Supply Chain